Dilemma between gastroprotection and cardiovascular prevention;Dilemma zwischen Magenschutz und Kardioprotektion

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 44, 2010, Pages 2193-2198

  Venerito, M ^a   Kandulski, A ^a   Malfertheiner, P ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Clopidogrel; drug interaction; proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CORONARY STENT; DRUG CROSS REACTIVITY; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HUMAN; LOSS OF FUNCTION MUTATION; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; STOMACH PROTECTION; THROMBOCYTE AGGREGATION INHIBITION;

ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HUMANS; LONG-TERM CARE; MUTATION; OMEPRAZOLE; PEPTIC ULCER HEMORRHAGE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 78049351476     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1267498     Document Type: Review

References (45)

1. Antman E M., Hand M, Armstrong P W. et al. 2007 Focused Update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008 117 296-329
2. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009 373 1849-60
3. Bhatt D L., Cryer B, Contant C F. et al. COGENT: A prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. San Fransico, CA Transcatheter Cardiovascular Therapeutics (TCT) 24.09.2009
4. Bhatt D L., Scheiman J, Abraham N S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008 52 1502-1517
5. Chan F K., Ching J Y., Hung L C. et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005 352 238-244
6. Chin M W., Yong G, Bulsara M K. et al. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007 102 2411-2416
7. Chow C K., Moayyedi P, Devereaux P J. Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn 2009 119 564-568
8. Collet J P., Hulot J S., Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with Clopidogrel after myocardial infarction: a cohort study. Lancet 2009 373 309-317
9. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. Erscheinungsdatum: 29.05.2009; Im Internet: www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf; letzter Zugriff 24.07.2010
10. Evanchan J, Donnally M R., Binkley P et al. Recurrence of acute myocardial Infarction in patients discharged on Clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction. Clin Cardiol 2010 33 168-171
11. Fischbach W, Malfertheiner P, Hoffmann J C. et al. S3-guideline helicobacter pylori and gastroduodenal ulcer disease of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. Z Gastroenterol 2009 47 1230-1263
12. Frere C, Cuisset T, Morange P E. et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008 101 1088-1093
13. Gaglia M A., Torguson R, Hanna N et al. Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes. Am J Cardiol 2010 105 833-838
14. Gilard M, Arnaud B, Cornily J C. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008 51 256-260
15. Gilard M, Arnaud B, Le Gal G et al. Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006 4 2508-2509
16. Grines C L., Bonow R O., Casey Jr D E. et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Dent Assoc 2007 138 652-655
17. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006 333 726-730
18. Hollopeter G, Jantzen H M., Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001 409 202-207
19. Ho P M., Maddox T M., Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 301 937-944
20. Hulot J S., Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006 108 2244-2247
21. Juurlink D N., Gomes T, Ko D T. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 180 713-718
22. Kandulski A, Venerito M, Malfertheiner P. Nichtsteroidale Antirheumatika (NSAR) an der Schnittstelle gastrointestinaler Nebenwirkungen und kardiovaskulärer Risiken. Dtsch Med Wochenschr 2009 134 1635-1640
23. Kwok C S., Loke Y K. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Aliment Pharmacol Ther 2010 31 810-823
24. Labenz J, Meyners W, Petersen K U. Clopidogrel und Protonenpumpeninhibitoren Fluch oder Segen? Dtsch Med Wochenschr 2010 135 203-206
25. Lai K C., Chu K M., Hui W M. et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006 4 860-865
26. Laine L, Hennekens C. Proton pump inhibitor and Clopidogrel interaction: Fact or Fiction? Am J Gastroenterol 2009 105 34-41
27. Lanas A, García-Rodríguez L A., Arroyo M T. et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 2007 102 507-515
28. Malek L A., Kisiel B, Spiewak M et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008 72 1165-1169
29. Mega J L., Close S L., Wiviott S D. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009 360 354-362
30. Montalescot G, Wiviott S D., Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009 373 723-731
31. ODonoghue M L., Braunwald E, Antman E M. et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009 374 989-997
32. Rassen J A., Choudhry N K., Avorn J et al. Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 2009 120 2322-2329
33. Ray W A., Murray K T., Griffin M R. et al. Outcomes with concurrent use of Clopidogrel and proton-pump inhibitors. Ann Intern Med 2010 152 337-345
34. Rosemary J, Adithan C. The pharmacogenetics of CYP 2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol 2007 2 93-109
35. Rude M K., Chey W D. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between? Gastroenterology 2009 137 1168-1171
36. Siller-Matula J M., Spiel A O., Lang I M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009 157 148.e1-5
37. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009 360 363-75
38. Small D S., Farid N A., Payne C D. et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008 48 475-484
39. Trenk D, Hochholzer W, Fromm M F. et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008 51 1925-1934
40. U.S. Food and Drug Administration. Clopidogrel Bisulfate (Plavix) Potential Interactions with Omeprazole (Prilosec) and Esomeprazole (Nexium) Ongoing Safety Review. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm190784.htm Erscheinungsdatum: 17.11.2009; Datum des Zugriffs 24.05.2010
41. U.S. Food and Drug Administration. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). www.fda.gov/cder/drug/early-comm/clopidogrel-bisulfate.htm Erscheinungsdatum: 31.01.2009; Datum des Zugriffs 24.05.2010
42. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008 29 2909-2945
43. Venerito M, Wex T, Malfertheiner P. Nonsteroidal anti-inflammatory drug-induced gastroduodenal bleeding: risk factors and prevention strategies. Pharmaceuticals 2010 3 2225-2237
44. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 310 827-830
45. Yusuf S, Zhao F, Mehta S R., et al, Clopidogrel in unstable angina to prevent recurrent events trail investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 494-502